

Date of report 22 Jun 2020

# Reported case interaction between Dolutegravir and Mineral supplements

## Drugs suspected to be involved in the DDI

Victim

**Dolutegravir** 

Dose adjustment performed

No

Start date
April 2, 2018

Daily Dose

50 (mg)

Administration Route

Oral

End date

**Ongoing** 

Perpetrator

**Mineral supplements** 

Daily Dose

420 (mg)

Dose adjustment performed

No

Administration Route

Oral

Start date

Unknown

End date

Unknown

# Complete list of drugs taken by the patient

Antiretroviral treatment

Dolutegravir/Abacavir/Lamivudine

Complete list of all comedications taken by the patient, included that involved in the DDI

Magnessium supplements

# **Clinical case description**

Gender Age

Female 40

eGFR (mL/min) Liver function impairment

>60 No

#### Description

40 year-old woman, diagnosed with HIV infection in April 2004. Since April 2018 on cART with DTG/ABC/3TC, with undetectable plasma viral load (pVL). In March 2019 pVL was 120 copies/mL, but she assured being adherent to cART. Three months after, repeated pVL was 380 copies/mL. TDM showed low dolutegravir Ctrough (0.38 μg/mL). Repeated adherence consultation revealed intake of Mg++ supplements (magnesium citrate, 420 mg QD) together with Triumeq at night. The patient was advised to stop taking magnesium at the same time with dolutegravir, and to take it either 2-3 hours before or 6 hours after taking dolutegravir. After several months she achieved undetectable pVL again.

### **Clinical Outcome**

## **Loss of efficacy**

## **Drug Interaction Probability Scale (DIPS)**

Score

#### 6 - Probable

#### **Editorial Comment**

Dolutegravir binds to divalent cations, such as magnesium, and forms a complex at the level of the gastro-intestinal tract which results in less dolutegravir being absorbed.

Dolutegravir should be administered 2 hours before or 6 hours after taking medications containing magnesium.

Dolutegravir should be administered 2 hours before or 6 hours after taking medications containing magnesium.

# **University of Liverpool Recommendation**

■ Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration

For more information click here